Promising new therapies for this important risk factor are far along in clinical testing. Wider measurement of Lp(a) levels is needed now.Read More
For the first time, a pharmacotherapy for overweight and obesity has reduced cardiovascular events in patients with established cardiovascular disease in the absence of type 2 diabetes.
A phase 1 study finds that lepodisiran can essentially eliminate Lp(a) from the circulation long enough to potentially allow once- or twice-yearly dosing. Phase 2 testing is now underway.
New study raises concerns about the use of potent coprescriptions to manage insomnia before and during the COVID-19 pandemic.
Autoimmunity may play a role in the pathogenesis of POTS in some patients, but a single causative antibody has not been identified. Antibody testing currently is recommended only when considering an alternative diagnosis.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
An observational study suggests that adding coronary artery calcium results to traditional risk models yields synergistic value and the promise of a precision medicine approach.
The novel aldosterone synthase inhibitor yielded particularly robust blood pressure reduction in trial participants with obesity.
Care pathways for this facial pain syndrome vary widely. The most recent U.K. guidelines emphasize the need for evidence-based care plans for multidisciplinary management.
How to be a resource for patients when it comes to climate change and their health.
The lipid-lowering drug’s treatment effect was greater in this prespecified analysis of high-risk patients without a prior cardiac event than in the overall trial’s secondary prevention cohort.
The FDA-mandated trial provides reassurance about risk of cardiovascular events, but only for middle-aged or older men with confirmed hypogonadism.